Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Condition: Moderate to Severe Chronic Plaque-type Psoriasis
MeSH terms: Psoriasis
Intervention: secukinumab 150 mg
Intervention description: sub-cutaneous secukinumab prefilled syringe 150 mg
Phase: Phase 3
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 331.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: psoriasis; secukinumab; immune-mediated systemic disease; papules; plaques; itching; weight

Summary:

      The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose
      (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
    

Eligibility criteria:

        Key Inclusion Criteria:

          -  Written informed consent must have been obtained before any assessment was performed.
             Where relevant, a legal representative will also have signed the informed study
             consent according to local laws and regulations.

          -  Subjects must have been able to understand and communicate with the investigator and
             comply with the requirements of the study.

          -  Men or women at least 18 years of age at time of screening.

          -  Body weight of ≥ 90 kg at the time of randomization.

          -  Chronic plaque-type psoriasis present for at least 6 months and diagnosed before
             randomization.

          -  Moderate to severe psoriasis as defined at randomization by:

               -  Psoriasis Area and Severity Index (PASI) score of 12 or greater, and

               -  Investigator's Global Assessment (IGA) mod 2011 score of 3 or greater (based on a
                  static scale of 0 - 4), and

               -  Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.

          -  Candidate for systemic therapy. This is defined as a subject having moderate to severe
             chronic plaque-type psoriasis that is inadequately controlled by:

               -  topical treatment and/or,

               -  phototherapy and/or,

               -  previous systemic therapy.

        Key Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttate psoriasis) at screening or Randomization.

          -  Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to
             be adhered to. Subjects not willing to limit ultraviolet (UV) light exposure (e.g.,
             sunbathing and / or the use of tanning devices) during the course of the study will be
             considered not eligible for this study since UV light exposure is prohibited. Note:
             administration of live vaccines 6 weeks prior to Randomization or during the study
             period is also prohibited.

          -  Previous exposure to secukinumab (AIN457) or any other biologic drug directly
             targeting Interleukin-17 (IL-17) or the IL-17 receptor.

          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives
             of enrollment, or within 4 weeks until the expected pharmacodynamic effect has
             returned to baseline, whichever is longer; or longer if required by local regulations.

          -  Pregnant or nursing (lactating) women

          -  History of lymphoproliferative disease or any known malignancy or history of
             malignancy of any organ system treated or untreated within the past 5 years,
             regardless of whether there is evidence of local recurrence or metastases (except for
             skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been
             treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the
             cervix or non-invasive malignant colon polyps that have been removed).

          -  History of hypersensitivity to any of the study drug constituents.